| Literature DB >> 29038428 |
Rita De Gasperi1,2,3, Sayyed Hamidi4, Lauren M Harlow1, Hanna Ksiezak-Reding5, William A Bauman1,4,6,7, Christopher P Cardozo8,9,10,11,12.
Abstract
Exosomes are vesicles released by many eukaryotic cells; their cargo includes proteins, mRNA and microRNA (miR) that can be transferred to recipient cells and regulate cellular processes in an autocrine or paracrine manner. While cells of the myoblast lineage secrete exosomes, it is not known whether skeletal muscle fibers (myofibers) release exosomes. In this study, we found that cultured myofibers release nanovesicles that have bilamellar membranes and an average size of 60-130 nm, contain typical exosomal proteins and miRNAs and are taken up by C2C12 cells. miR-133a was found to be the most abundant myomiR in these vesicles while miR-720 was most enriched in exosomes compared to parent myofibers. Treatment of NIH 3T3 cells with myofiber-derived exosomes downregulated the miR-133a targets proteins Smarcd1 and Runx2, confirming that these exosomes have biologically relevant effects on recipient cells. Denervation resulted in a marked increase in miR-206 and reduced expression of miRs 1, 133a, and 133b in myofiber-derived exosomes. These findings demonstrate that skeletal muscle fibers release exosomes which can exert biologically significant effects on recipient cells, and that pathological muscle conditions such as denervation induce alterations in exosomal miR profile which could influence responses to disease states through autocrine or paracrine mechanisms.Entities:
Mesh:
Substances:
Year: 2017 PMID: 29038428 PMCID: PMC5643439 DOI: 10.1038/s41598-017-13105-9
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1EM characterization of nanovesicles released by dispersed muscle fibers. Dispersed mouse hindlimb muscle fibers were incubated for 48 hours. Nanovesicles were isolated by ultracentrifugation of conditioned medium then stained with uranyl acetate (A,B) or labeled with 10-nm immunogold particles using antibodies against the exosomal membrane markers CD63 (C–F), CD81 (G–J) and CD9 (K), and stained with uranyl acetate. Nanovesicles were imaged by electron microscopy. Scale bar: 100 nm.
Figure 2Size distribution and uptake by cells of nanovesicles released by dispersed muscle fibers. Dispersed mouse muscle fibers were incubated for 48 hours, after which nanovesicles were isolated by differential centrifugation. (A and B) The size distribution and concentration of particles was analyzed by nanoparticle tracking. (C and E) Nanovesicles were labeled with PKH67 dye and overlaid on cultures of proliferating C2C12 cells. The control cells were treated with an equal volume of dye-treated PBS. After 5 hours, the cells were fixed, stained with phalloidin to visualize cell bodies, counterstained with DAPI to label nuclei and imaged by confocal microscopy. Panel (C) shows control cells incubated in media containing PKH67-treated PBS; panels (D and E) show cells incubated with PKH67-labeled nanoparticles. In these images, nanoparticles are green, phalloidin is red and nuclei are blue (DAPI).
nCounter analysis: Significantly altered miRs in denervated fibers
| miR | ID | Mean Sham | SD Sham | Mean DN | SD DN | fold-change | P value |
|---|---|---|---|---|---|---|---|
| mmu-let-7e | MIMAT0000524 | 400 | 17 | 287 | 68 | 0.72 | 0.049 |
| mmu-miR-1 | MIMAT0000123 | 21018 | 5442 | 10364 | 2535 | 0.49 | 0.037 |
| mmu-miR-100 | MIMAT0000655 | 399 | 45 | 209 | 67 | 0.52 | 0.015 |
| mmu-miR-106a + mmu-miR-17 | MIMAT0000385 | 132 | 6 | 171 | 14 | 1.29 | 0.011 |
| mmu-miR-132 | MIMAT0000144 | 124 | 26 | 64 | 10 | 0.52 | 0.021 |
| mmu-miR-133a | MIMAT0000145 | 10120 | 1261 | 4685 | 813 | 0.46 | 0.003 |
| mmu-miR-133b | MIMAT0000769 | 393 | 48 | 632 | 89 | 1.61 | 0.015 |
| mmu-miR-143 | MIMAT0000247 | 350 | 143 | 108 | 43 | 0.31 | 0.048 |
| mmu-miR-145 | MIMAT0000157 | 620 | 157 | 239 | 28 | 0.38 | 0.014 |
| mmu-miR-148a | MIMAT0000516 | 100 | 11 | 67 | 12 | 0.67 | 0.027 |
| mmu-miR-16 | MIMAT0000527 | 927 | 96 | 648 | 130 | 0.70 | 0.040 |
| mmu-miR-188-5p | MIMAT0000217 | 131 | 5 | 111 | 12 | 0.84 | 0.049 |
| mmu-miR-206 | MIMAT0000239 | 649 | 112 | 16354 | 5002 | 25.19 | 0.006 |
| mmu-miR-27a | MIMAT0000537 | 460 | 31 | 849 | 105 | 1.84 | 0.004 |
| mmu-miR-29b | MIMAT0000127 | 212 | 12 | 316 | 59 | 1.49 | 0.040 |
| mmu-miR-29c | MIMAT0000536 | 1467 | 253 | 740 | 137 | 0.50 | 0.012 |
| mmu-miR-30a | MIMAT0000128 | 759 | 191 | 435 | 53 | 0.57 | 0.047 |
| mmu-miR-30b | MIMAT0000130 | 270 | 12 | 170 | 38 | 0.63 | 0.013 |
| mmu-miR-30d | MIMAT0000515 | 319 | 40 | 181 | 32 | 0.57 | 0.010 |
| mmu-miR-365 | MIMAT0000711 | 272 | 81 | 127 | 31 | 0.46 | 0.044 |
| mmu-miR-378 | MIMAT0003151 | 3154 | 339 | 1982 | 271 | 0.63 | 0.009 |
Data are mean, normalized counts for 3 Sham and 3 Denervated animals. Fold-change was calculated as mean counts for the denervated group/mean counts for the sham group. SD, standard deviation.
Figure 3Expression of myomiRs and other selected miR targets in fiber-derived exosomes. Fibers derived from mixed calf muscle were cultured for 48 hours in exosome- free medium. RNA was isolated from fibers (A) and corresponding nanovesicles (B) and miR expression analyzed by qPCR. The expression is relative to that of miR-22 which was the lowest expressed among the targets tested. The data are from three independent fiber/exosomes preparations.
Figure 4qPCR evaluation of the effect of denervation on miRs expression. Dispersed muscle fibers were isolated from mouse EDL muscle 7 days after sciatic nerve transection or sham transection and maintained in culture in exosome-free medium for 48 hours. RNA was extracted from dispersed fibers (A) and corresponding nanovesicles preparations (B) and miRs expression levels were determined by qPCR. Data are mean values ± SD for 5 animals per group except for the exosomes produced by denervated fibers (n = 4). *p < 0.05; **p < 0.01; ***p < 0.001.
Targets of dysregulated miRs present in exosomes released by denervated fibers.
| Ingenuity Canonical Pathways | -log(p-value) | Molecules |
|---|---|---|
| Myc Mediated Apoptosis Signaling | 3.19E + 00 | YWHAQ, CASP9, IGF1, IGF1R, BCL2 |
| IGF-1 Signaling | 3.18E + 00 | YWHAQ, CTGF, CASP9, IGF1, IGF1R, SRF |
| Calcium Signaling | 2.70E + 00 | HDAC4, MEF2A, TPM3, TPM1, NFATC4, TPM4, TPM2 |
| Purine Ribonucleosides Degradation to Ribose-1-phosphate | 2.58E + 00 | PNP, PGM2 |
| Huntington’s Disease Signaling | 2.55E + 00 | HDAC4, CASP9, IGF1, BDNF, IGF1R, POLR2K, DNAJB1, EGFR |
| UDP-N-acetyl-D-galactosamine Biosynthesis II | 2.30E + 00 | GNPNAT1, GNPDA2 |
| STAT3 Pathway | 2.23E + 00 | PIM1, IGF1R, EGFR, BCL2 |
| PTEN Signaling | 2.18E + 00 | CASP9, INPP5F, IGF1R, EGFR, BCL2 |
| Estrogen-Dependent Breast Cancer Signaling | 2.14E + 00 | IGF1, IGF1R, ESR1, EGFR |
| Cardiac Hypertrophy Signaling | 2.04E + 00 | HAND2, IGF1, RHOA, IGF1R, SRF, MEF2A, NFATC4 |
| PEDF Signaling | 2.01E + 00 | BDNF, RHOA, SRF, BCL2 |
| Hepatic Fibrosis/Hepatic Stellate Cell Activation | 2.01E + 00 | MET, CTGF, IGF1, IGF1R, EGFR, BCL2 |
| Xanthine and Xanthosine Salvage | 2.00E + 00 | PNP |
| Chondroitin Sulfate Biosynthesis (Late Stages) | 1.90E + 00 | UST, CHSY1, CHST11 |
| Clathrin-mediated Endocytosis Signaling | 1.86E + 00 | MET, IGF1, PICALM, GAK, ITGB4, F2 |
| Epithelial Adherens Junction Signaling | 1.82E + 00 | MET, NOTCH2, NOTCH3, RHOA, EGFR |
| Semaphorin Signaling in Neurons | 1.81E + 00 | MET, RHOA, NRP1 |
| Cholecystokinin/Gastrin-mediated Signaling | 1.74E + 00 | RHOA, SRF, MEF2A, EGFR |
| Guanine and Guanosine Salvage I | 1.71E + 00 | PNP |
| Adenine and Adenosine Salvage I | 1.71E + 00 | PNP |
The top 20 most significant pathways represented by validated targets for dysregulated miRs present in exosomes released by denervated fibers are listed. A complete listing of significant pathways is shown in Table S2.
Figure 5Fiber-derived exosomes modulate Smarcd1 and Runx2 expression. NIH3T3 grown in exosome- depleted medium were treated with fiber-derived exosomes (4 μg/ml) or PBS for 48 hours. The expression of Smarcd1 and Runx2 was analyzed by Western blot. Representative blots are shown in panel (A). Panel (B) shows the quantitation of Smarcd1 and Runx2 expression relative to Gapdh for three separate experiments, each with 3 wells per condition for a total of 9 samples for each condition. **p < 0.005, ****p < 0.0001. Full-length blots are presented in Supplementary Figure S1.